[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 733
Citations 0
Correction
August 14, 2013

Clarification of Data

JAMA. 2013;310(6):647. doi:10.1001/jama.2013.48989

In the Clinical Review entitled “Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: A Systematic Review,” published in the March 27, 2013, issue of JAMA (2013;309[12]:1278-1288. doi:10.1001/jama.2013.2049), a clarification should be made in 2 places. On page 1281, under the heading “Rhinitis,” the third sentence should read “The majority of studies (94%) demonstrated greater improvement in the sublingual immunotherapy groups vs placebo.” In Table 1, second row, “Rhinitis or rhinoconjunctivitis symptoms scores,” in column 7, “Findings,” should read “The majority of studies showed greater improvement in symptoms in the sublingual immunotherapy group vs placebo.” This article has been corrected online.

×